Evidence map›Paper›PMID 27321180›Full record

ArticleOncogene2017

cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation.

C Metheetrairut, B D Adams, S Nallur, J B Weidhaas, F J Slack

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Animal Models to Study MicroRNA Function.Advances in cancer research · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

C MetheetrairutDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
B D AdamsDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
S NallurDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
J B WeidhaasDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
F J SlackDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
Yale University · USHarvard University · USSiriraj Hospital · TH

Funding

Training in Genomics and Proteomics TechnologiesT32HG003198 · NHGRI · YALE UNIVERSITY · PI BREAKER, RONALD R · 2004 to 2015
$4.9M
MicroRNAs in agingR01AG033921 · NIA · YALE UNIVERSITY · PI SLACK, FRANK J. · 2009 to 2018
$3.3M
MicroRNAs to Understand Cause and Outcome in Breast CancerR01CA157749 · NCI · YALE UNIVERSITY · PI SLACK, FRANK J., WEIDHAAS, JOANNE B · 2012 to 2016
$1.7M
Let-7 microRNAs in Lung Cancer: Altering Growth and RadioresistanceR01CA131301 · NCI · YALE UNIVERSITY · PI SLACK, FRANK J., WEIDHAAS, JOANNE B · 2009 to 2013
$1.7M
NCI NIH HHS R01 CA131301NCI NIH HHS R01 CA157749NHGRI NIH HHS T32 HG003198NIA NIH HHS R01 AG033921
6 · The paper itself

Abstract

Elucidating the mechanisms involved in sensitizing radioresistant tumors to ionizing radiation (IR) treatments while minimizing injury to surrounding normal tissue is an important clinical goal. Due to their sequence-derived specificity and properties as gene regulators in IR-affected pathways, microRNAs (miRNAs) could serve as adjuvant therapeutic agents that alter cellular sensitivity to radiation treatment. To identify radiosensitizing miRNAs, we initially utilized the Caenorhabditis elegans vulval cell model, an in vivo system developed to study IR-dependent radiosensitivity as a measure of clonogenic cell death. We tested several candidate miRNA-deletion mutants post γ-irradiation and identified cel-mir-237 as a miRNA which when deleted caused animals to be more resistant to IR, whereas cel-mir-237 overexpressing strains were IR sensitive. In addition, wild-type animals downregulated cel-mir-237 levels post IR in a time-dependent manner. We identified jun-1 (JUN transcription factor homolog) as a novel target of cel-mir-237. Specifically, jun-1 transcript levels increased in wild-type animals post γ-irradiation, and loss of cel-mir-237 also resulted in higher jun-1 expression. As expected, loss of jun-1 resulted in IR sensitivity, similar to the phenotype of cel-mir-237 overexpressors. As miR-237 is the homolog of human miR-125, we validated our findings in MCF-7 and MDA-MB-231 breast cancer cell lines, which harbor lower hsa-miR-125b levels than normal human mammary epithelial cells (HMECs). Forced expression of hsa-miR-125b in these cells resulted in radiosensitivity, as seen by reduced clonogenic survival, enhanced apoptotic activity and enhanced senescence post IR. Finally, re-expression of c-JUN in MDA-MB-231 cells promoted radioresistance and abrogated miR-125-mediated radiosensitization. Our findings suggest that overexpression of cel-mir-237 and its homolog, hsa-miR-125b, functions as sensitizers to γ-irradiation in both a nematode in vivo model and breast cancer cells, and could potentially be utilized as an adjuvant therapeutic to enhance radiation sensitivity.

Indexed as

AnimalsCaenorhabditis elegansCaenorhabditis elegans ProteinsCell Line, TumorHumansMaleMCF-7 CellsMicroRNAsRadiation, IonizingSignal TransductionTranscription FactorsCaenorhabditis elegans ProteinsJUN-1 protein, C elegansMicroRNAsMIRN125 microRNA, humanTranscription Factors

Identifiers

PMID27321180
PMCPMC5173455
OpenAlexW2462677535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.